Psyence Biomedical (PBM) said Wednesday it has received extension from Nasdaq through Dec. 31 for demonstrating compliance with all continued listing requirements.
During the hearing, the company provided a plan to the regulator regarding compliance with listing requirements including the $1 minimum bid price rule, the $1 million market value, and the $2.5 million minimum shareholders' equity requirement, Psyence added.
The life science biotechnology company has also asked the regulator to shift it to the Nasdaq Capital Market from the Nasdaq Global Market.
Additionally, Psyence said it received shareholder nod on Nov. 12 for a 1-for-75 share consolidation plan to meet the $1 minimum bid price requirement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。